文献速递瓣膜病与结构性心脏病冠心病

NOTION-2 试验三年随访:TAVR 与 SAVR 治疗年轻低危三叶瓣或二叶瓣主动脉瓣狭窄

Three-Year Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients With Tricuspid or Bicuspid Aortic Stenosis.
PubMed 文献 · Circulation · 2025-08-30

NOTION-2 研究将 370 例 60 至 75 岁、外科低危的重度主动脉瓣狭窄患者随机分配至 TAVR 或外科换瓣,随访 3 年。主要复合终点在 TAVR 组为 16.1%、外科组为 12.6%(HR 1.3,95%CI 0.8-2.2),两组结构瓣毁损与生物瓣衰败率均低且相近。

要点

  • 低危 60 至 75 岁患者 TAVR 与外科换瓣 3 年主要复合终点无显著差异。
  • 二叶瓣患者 TAVR 主要终点数值更高但未达统计学显著(HR 2.9,95%CI 0.9-9.0)。
  • 两组 3 年结构瓣毁损与生物瓣衰败率均低且相近。

核心结论

  • 60 至 75 岁外科低危重度主动脉瓣狭窄患者中,TAVR 与外科换瓣 3 年临床结局相似。
  • 两种术式结构瓣毁损率与再干预需求均低。

研究设计与样本

  • NOTION-2 为随机对照试验,纳入 370 例 60 至 75 岁重度三叶瓣或二叶瓣主动脉瓣狭窄患者,按 1:1 随机分配至 TAVR 或外科换瓣。
  • 患者平均年龄 71.1 岁,平均 STS 预测死亡风险 1.2%。
  • 本随访报告至 3 年的临床与超声心动图结局。

主要发现

  • 3 年主要复合终点(死亡、卒中或手术/瓣膜/心衰相关住院)TAVR 组 16.1% 对 外科组 12.6%(HR 1.3,95%CI 0.8-2.2)。
  • 三叶瓣患者主要终点 TAVR 14.5% 对 外科 14.4%。
  • 二叶瓣患者主要终点 TAVR 20.4% 对 外科 7.8%(HR 2.9,95%CI 0.9-9.0),无统计学显著性。
  • 3 年中度及以上结构瓣毁损 TAVR 4.5% 对 外科 5.2%(HR 1.2,95%CI 0.4-3.1)。
  • 生物瓣衰败率 TAVR 1.6% 对 外科 2.9%。

临床怎么用

  • 对于 60 至 75 岁外科低危重度主动脉瓣狭窄患者,TAVR 可作为与外科换瓣相当的选择。
  • 二叶瓣患者选择 TAVR 时需个体化评估,因该亚组主要终点数值上不利于 TAVR 但未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcatheter aortic valve replacement (TAVR) is increasingly performed in younger, low surgical risk patients. The NOTION-2 study (The Nordic Aortic Valve Intervention) reports midterm outcomes in low-risk patients age 60 to 75 years with severe tricuspid or bicuspid aortic stenosis undergoing TAVR or surgical valve replacement. METHODS: A total of 370 patients (mean age, 71.1 years; mean Society of Thoracic Surgeons Predicted Risk of Mortality, 1.2%) were enrolled and randomized 1:1 to TAVR or surgery. This follow-up study reports clinical and echocardiographic outcomes up to 3 years of follow-up. RESULTS: At 3 years, the primary composite end point (death, stroke, or procedure-, valve-, or heart failure-related hospitalization) occurred in 16.1% of patients with TAVR versus 12.6% in surgical patients (hazard ratio, 1.3; 95% CI, 0.8-2.2%; I=0.4). Among patients with tricuspid aortic stenosis, rates were similar (14.5% versus 14.4%), whereas patients with bicuspid aortic stenosis had a statistically nonsignificant higher risk with TAVR (20.4% versus 7.8%; hazard ratio, 2.9; 95% CI, 0.9-9.0). The risk of moderate or greater structural valve deterioration at 3 years was 4.5% and 5.2% for transcatheter and surgical aortic bioprostheses, respectively (hazard ratio, 1.2; 95% CI, 0.4-3.1). Bioprosthetic valve failure rates were also comparable: 1.6% in the TAVR group and 2.9% in the surgical group. CONCLUSIONS: For patients age 60 to 75 years with severe aortic stenosis who are at low surgical risk, 3-year clinical outcomes are similar between TAVR and surgery. Both procedures are associated with low rates of structural valve deterioration and need for reintervention. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02825134.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Jørgensen TH, Savontaus M, Willemen Y, et al. Three-Year Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients With Tricuspid or Bicuspid Aortic Stenosis. Circulation. 2025. PMID: 40884768. doi:10.1161/CIRCULATIONAHA.125.076678

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。